Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study
Graeme Jones,Anthony Sebba,Jieruo Gu,Mitchell B. Lowenstein,Armando Calvo,Juan J. Gomez-Reino,Daniel Siri,Matija Tomšič,Emma Alecock,Thasia G. Woodworth,Mark C. Genovese +10 more
Reads0
Chats0
TLDR
Tocilizumab monotherapy is better than methotrexate monotherapy, with rapid improvement in RA signs and symptoms, and a favourable benefit–risk, in patients for whom treatment with methotRexate or biological agents has not previously failed.Abstract:
Background: The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. Objective: To evaluate through the AMBITION study the efficacy and safety of tocilizumab monotherapy versus methotrexate in patients with active RA for whom previous treatment with methotrexate/biological agents had not failed. Methods: This 24-week, double-blind, double-dummy, parallel-group study, randomised 673 patients to either tocilizumab 8 mg/kg every 4 weeks, or methotrexate, starting at 7.5 mg/week and titrated to 20 mg/week within 8 weeks, or placebo for 8 weeks followed by tocilizumab 8 mg/kg. The primary end point was the proportion of patients achieving American College of Rheumatology (ACR) 20 response at week 24. Results: The intention-to-treat analysis demonstrated that tocilizumab was better than methotrexate treatment with a higher ACR20 response (69.9 vs 52.5%; p 3×– Conclusion: Tocilizumab monotherapy is better than methotrexate monotherapy, with rapid improvement in RA signs and symptoms, and a favourable benefit–risk, in patients for whom treatment with methotrexate or biological agents has not previously failed. Trial registration number: NCT00109408read more
Citations
More filters
Journal ArticleDOI
Stellenwert von interleukingerichteten Therapien bei Autoimmunkrankheiten
TL;DR: Understanding the pathophysiology of autoimmune diseases enables the identification of new targets for more precise pharmacotherapies, Ideally, these should not only be highly effective but also have a better safety profile.
Journal ArticleDOI
A Review on Comparison of Effectiveness and Safety of Disease Modifying Anti-Rheumatoid Drugs Used in Patients with Rheumatoid Arthritis
P.P. Muhamed Faris,K. Sreejith,B. Athulnadh,K.V. Musaina Thasneem,Cherakkulath C Neena,Namitha Maniyan +5 more
TL;DR: The comparison in between each disease modifying anti rheumatoid drug (DMARD) monotherapy, combination with monotherapy and also combination with combination therapy shows methotrexate would be the preferred DMARD.
Journal ArticleDOI
Prevalence of adverse reactions to intravenously administered originator biologics in patients with rheumatoid arthritis: A 5-year retrospective study
Haya Mohammed Almalag,Shiekha S AlAujan,Hawazin Alhazzani,Lamia A. Alzamel,Reem S. Tashkandi,Hussain Alarfaj,Abdurhman S. Al-Arfaj,Mohammed A. Omair +7 more
TL;DR: In this paper , the authors evaluated the prevalence, types, and predictors of adverse drug reactions (ADRs) following long-term IV originator biologic use in patients with RA.
Journal ArticleDOI
Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis.
Ahmad Y. Abuhelwa,Ahmad Y. Abuhelwa,David J. R. Foster,Arkady T. Manning-Bennett,Michael J. Sorich,Susanna Proudman,Susanna Proudman,Michael D. Wiese,Ashley M. Hopkins +8 more
TL;DR: In this article, Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular disease (CVD) and treatment for CVD may involve pharmacological agent, such as antirheumatic drugs.
Journal ArticleDOI
Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis.
TL;DR: To evaluate safety and efficacy of tocilizumab (TCZ) in a post‐approval pilot study among selected Iranian patients with moderate to severe rheumatoid arthritis and inadequate responses to disease‐modifying antirheumatic drugs (DMARDs).
References
More filters
Journal ArticleDOI
Modified disease activity scores that include twenty-eight-joint counts : development and validation in a prospective longitudinal study of patients with rheumatoid arthritis
M.L.L. Prevoo,M.A. van 't Hof,H.H. Kuper,M.A. van Leeuwen,L. B. A. Van De Putte,P.L.C.M. van Riel +5 more
TL;DR: The Modified DAS that included 28-joint counts were able to discriminate between high and low disease activity (as indicated by clinical decisions of rheumatologists) and are as valid as disease activity scores that include more comprehensive joint counts.
Journal ArticleDOI
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
David T. Felson,David T. Felson,Jennifer J. Anderson,Jennifer J. Anderson,Maarten Boers,Claire Bombardier,Claire Bombardier,Daniel E. Furst,Daniel E. Furst,Charles H. Goldsmith,Charles H. Goldsmith,Linda M. Katz,Linda M. Katz,Robert W. Lightfoot,Robert W. Lightfoot,Harold E. Paulus,Harold E. Paulus,Vibeke Strand,Vibeke Strand,Peter Tugwell,Peter Tugwell,Michael E. Weinblatt,Michael E. Weinblatt,H. James Williams,H. James Williams,Frederick Wolfe,Stephanie Kieszak +26 more
TL;DR: The results suggest that the definition of improvement presented is statistically powerful and does not identify a large percentage of placebo-treated patients as being improved, which the authors hope will be used widely in RA trials.
Journal ArticleDOI
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Ravinder N. Maini,E W St Clair,F. C. Breedveld,Daniel E. Furst,Joachim R. Kalden,Michael H. Weisman,Josef S. Smolen,Paul Emery,G Harriman,Marc Feldmann,Peter E. Lipsky +10 more
TL;DR: Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group.
Journal ArticleDOI
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Ernest Choy,Gabriel S. Panayi +1 more
TL;DR: Current slow-acting antirheumatic drugs have limited efficacy and many side effects and do not improve the long-term prognosis of rheumatoid arthritis.
Journal ArticleDOI
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Joan M. Bathon,Richard J. Martin,Roy Fleischmann,John Tesser,Michael Schiff,Edward C. Keystone,Mark C. Genovese,Mary Chester M. Wasko,Larry W. Moreland,Arthur L. Weaver,Joseph A. Markenson,Barbara K. Finck +11 more
TL;DR: Subcutaneous [corrected] etanercept acted more rapidly to decrease symptoms and slow joint damage in patients with early active rheumatoid arthritis.
Related Papers (5)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maya H Buch,Maya H Buch,Gerd R Burmester,Maxime Dougados,Paul Emery,Paul Emery,Cécile Gaujoux-Viala,Laure Gossec,Jackie L Nam,Jackie L Nam,Sofia Ramiro,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Neil Betteridge,Johannes W. J. Bijlsma,Maarten Boers,Frank Buttgereit,Bernard Combe,Maurizio Cutolo,Nemanja Damjanov,Johanna M. W. Hazes,Marios Kouloumas,Tore K Kvien,Xavier Mariette,Karel Pavelka,Piet L. C. M. van Riel,Andrea Rubbert-Roth,Marieke Scholte-Voshaar,David Scott,T. Sokka-Isler,John B. Wong,Désirée van der Heijde +35 more